Dr Rafael Sanchez-Salas talks to ecancer at the ASCO GU 2014 cancer congress.

Several indicators of intermittent androgen deprivation (IAD) outcomes in prostate cancer have been interpreted as potentially predictive, including prostate-specific antigen (PSA) nadir following first on-treatment period, off-phase interval duration and PSA doubling time. Improvement of the forecast of clinical outcomes is expected through identification and analysis of the different types of off-treatment period.